Protection of Cardiovascular Function With Crocin in BrEast Cancer Patients Undergoing Radiotherapy and Chemotherapy (ProtECtion)
Breast Cancer
About this trial
This is an interventional prevention trial for Breast Cancer focused on measuring Breast cancer, Cancer therapy-related cardiac dysfunction, Crocin, Echocardiography, Speckle tracking technology
Eligibility Criteria
Inclusion criteria:
- Age 25-80 years old, female;
- Patients diagnosed with breast cancer by histopathology;
- Patients who plan to receive adjuvant radiotherapy/chemotherapy or combined adjuvant trastuzumab or pertuzumab targeted therapy;
- Patients who completed at least 6 cycles of treatment after enrollment;
Exclusion criteria:
- pregnant or breastfeeding women;
- Patients with poor echocardiographic image quality;
- Persistent atrial fibrillation and severe arrhythmia affect the collection and analysis of ultrasound data;
- Patients who are participating in other clinical studies.
Sites / Locations
- Qilu Hospital of Shandong UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Crocin group
placebo group
The chemotherapy/radiotherapy protocols are made by oncologists adopted for patients depending on specific conditions , take saffron total glucosides tablets(provided by Reyoung Pharmaceutical Co., Ltd.) for 8 days during each chemotherapy (started on the 1st day before chemotherapy), 4 tablets/time, 3 times a day.
Undergoing chemotherapy/radiotherapy protocols as planned, take placebo piece during(the same appearance of crocin tablets, production unit:Reyoung Pharmaceutical Co., Ltd.) for 8 days during each chemotherapy (started on the 1st day before chemotherapy), 4 tablets/time, 3 times a day